Company intelligence / Profile preview
Xanodyne Pharmaceuticals, Inc.
Newport, Kentucky, United Statesxanodyne.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Xanodyne was a specialty pharmaceutical company that marketed products for women's healthcare and pain management. Their most notable product was Zipsor (diclofenac potassium), a low-dose NSAID for mild to moderate acute pain that received FDA approval in June 2009[8]. The company appears to have wound down operations, selling rights to pain medication Roxicodone to Mallinckrodt[4].
- Therapeutic areas
- Women's HealthNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Ferring Pharmaceuticals (co-promotion agreement for Zipsor)[10]
Beyond the preview
Go deeper on Xanodyne Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xanodyne Pharmaceuticals, Inc..